Trial Profile
Randomized Study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine, Topotecan and Cyclophosphamide for Patients With Intermediate Risk Rhabdomyosarcoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Dactinomycin (Primary) ; Filgrastim (Primary) ; Sargramostim (Primary) ; Topotecan (Primary) ; Vincristine (Primary)
- Indications Rhabdomyosarcoma; Sarcoma
- Focus Therapeutic Use
- 30 Sep 2009 Planned end date (Dec 2013) added as reported by ClinicalTrials.gov.
- 21 Sep 2009 Results have been published in the Journal of Clinical Oncology.
- 30 Jun 2009 Additional lead trial investigators (Peri Kamalakar, Michael Harris) identified as reported by New Jersey Cancer Trial Connect record.